Press Kit
Salvat at a glance
If you are a media professional and wish to receive more information, please send us an email at media@svt.com.
Salvat’s News and Press kit
Media
Salvat at a glance
Press Kit
What are we doing right now
News
Media
Salvat at a glance
If you are a media professional and wish to receive more information, please send us an email at media@svt.com.
English Version PDF
What are we doing right now
Cookie | Duration | Description |
---|---|---|
_ga | 2 years | Google Analytics |
_gat_gtag_UA_112188601_1 | 2 years | Google Analytics |
_gid | 2 years | Google Analytics |
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
ip2location_redirection_first_visit | session | Mostrar las páginas de la web en el idioma seleccionado / Browse this website pages in the selected language |
PHPSESSID | session | Identificador de sesión PHP / PHP session id |
prescriptionModalAccepted | session | Identificador de sesión PHP / PHP session id |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
wpml_browser_redirect_test | session | Mostrar las páginas de la web en el idioma seleccionado / Browse this website pages in the selected language |
_icl_visitor_lang_js | session | Mostrar las páginas de la web en el idioma seleccionado / Browse this website pages in the selected language |
Salvat participated in the CPhI North America Congress
/in Salvat International, Salvat Spain, Salvat USA /by admininformaticaSalvat participated in the CPhI North America Congress, which annually gathers the most important companies of North America. This year it was held in Chicago, where we held many meetings with other pharmaceutical companies to explore opportunities that allow us to continue developing our activity in the United States.
Salvat and Pharmaloop participated in the CPhI Worldwide Congress
/in Salvat International, Salvat Spain, Salvat USA /by Carme LopezSalvat and Pharmaloop participated in the CPhI Worldwide Congress, which annually gathers the most important companies in the pharmaceutical world. This year it was held in Madrid, where both companies had the opportunity to hold many meetings with other pharmaceutical companies to explore opportunities that allow us to increase our activities internationally.
Laboratorios Salvat has participated in the consortium created for the development of the INDREYE research project “Innovative solutions for the treatment and diagnosis of dry eye syndrome”
/in Salvat Spain /by Carme LopezLaboratorios Salvat has participated in the consortium created for the development of the INDREYE research project “Innovative solutions for the treatment and diagnosis of dry eye syndrome” funded by the Spanish National Program of Public-Private Cooperation, subprogram INNPACTO, 2012 call. This program is co-financed by the European Union through the European regional development fund (ERDF/FEDER).
Laboratorios SALVAT maintains the rating of ‘VERY GOOD’ in the PROFARMA call in 2018
/in Salvat Spain /by Carme LopezOn July 26, 2018, the Spanish Ministry of Industry, Commerce and Tourism, through the General Secretariat of Industry and Small and Medium Enterprises resolved to grant Laboratorios Salvat its classification within Group A: Companies with significant research activity with own pharmaceutical production plant or its own basic or preclinical R & D center, with the […]
Laboratorios Salvat completes patient recruitment for the CIFLOTEX trial
/in Salvat International, Salvat USA /by Carme LopezOn August 30th 2018, the enrolment of patients into the CIFLOTEX clinical trial was completed. This study has been carried out in 45 US centers, and 493 patients suffering from Acute Otitis Externa (AOE) have been included. The objective of the study is to assess the efficacy and safety of our combination of Ciprofloxacin + […]